Novo Nordisk has been in diabetes for a unique 90 years and holds the largest share of the diabetes market worldwide with a promising future secured by a strong R&D pipeline, not only in diabetes, but also in haemophilia and other bio-pharm medicines.
Peter Meeus, UK General Manager of Novo Nordisk, explains the reasons behind their decision to join:
"As a growing player in the UK pharmaceutical market, we felt the time was right to join the ABPI. The ABPI has undergone real transformation in recent years and we are confident that as our business continues to grow in the UK, ABPI engagement will complement what we are doing to ensure we are better positioned to face the challenges and the opportunities in an increasingly dynamic business setting for the UK pharmaceutical industry."
Stephen Whitehead, Chief Executive of the ABPI, welcomed Novo Nordisk’s decision to join the ABPI:
"Novo Nordisk is a very welcome and important addition to our membership and will further strengthen the ABPI as the voice of the pharmaceutical industry. Novo Nordisk has joined a full service membership organisation that continues to shape the environment to make the UK an attractive destination for the research and development of life changing medicines. We will be looking to support them and our wider membership to ensure that once a medicine has been approved for use in the UK, the NHS is able to adopt it and patients can fully realise its benefits."
ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7808 641810 or +44 (0) 7850 312064
Notes to editor
About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit www.novonordisk.co.uk
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
For a list of full ABPI members, visit our Full Member list
on the ABPI website.